Welcome!

News Feed Item

Diabetic Macular Edema Global Clinical Trials Review, H2, 2013

LONDON, April 8, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Diabetic Macular Edema Global Clinical Trials Review, H2, 2013


Diabetic Macular Edema Global Clinical Trials Review, H2, 2013

Summary

GlobalData's clinical trial report, "Diabetic Macular Edema Global Clinical Trials Review, H2, 2013" provides data on the Diabetic Macular Edema clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Macular Edema . It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Macular Edema . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Diabetic Macular Edema 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by BRIC Nations 15
Clinical Trials by G7 Nations 16
Clinical Trials in G7 Nations by Trial Status 17
Clinical Trials by E7 Nations 18
Clinical Trials in E7 Nations by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Unaccomplished Trials of Diabetic Macular Edema 23
Subjects Recruited Over a Period of Time 27
Prominent Sponsors 28
Top Companies Participating in Diabetic Macular Edema Therapeutics Clinical Trials 30
Prominent Drug Comparison 32
Clinical Trial Profiles 33
Clinical Trial Overview of Top Companies 33
Allergan, Inc. 33
Clinical Trial Overview of Allergan, Inc. 33
Novartis AG 35
Clinical Trial Overview of Novartis AG 35
F. Hoffmann-La Roche Ltd. 37
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 37
Regeneron Pharmaceuticals, Inc. 38
Clinical Trial Overview of Regeneron Pharmaceuticals, Inc. 38
Pfizer Inc. 39
Clinical Trial Overview of Pfizer Inc. 39
Bayer AG 40
Clinical Trial Overview of Bayer AG 40
Alimera Sciences, Inc. 41
Clinical Trial Overview of Alimera Sciences, Inc. 41
Santen Pharmaceutical Co., Ltd. 42
Clinical Trial Overview of Santen Pharmaceutical Co., Ltd. 42
Bausch & Lomb Incorporated 43
Clinical Trial Overview of Bausch & Lomb Incorporated 43
Clinical Trial Overview of Top Institutes / Government 44
Diabetic Retinopathy Clinical Research Network 44
Clinical Trial Overview of Diabetic Retinopathy Clinical Research Network 44
National Eye Institute 45
Clinical Trial Overview of National Eye Institute 45
Johns Hopkins University 46
Clinical Trial Overview of Johns Hopkins University 46
Shahid Beheshti University of Medical Sciences 47
Clinical Trial Overview of Shahid Beheshti University of Medical Sciences 47
The University of Sydney 48
Clinical Trial Overview of The University of Sydney 48
Moorfields Eye Hospital NHS Foundation Trust 49
Clinical Trial Overview of Moorfields Eye Hospital NHS Foundation Trust 49
Medical University of Vienna 50
Clinical Trial Overview of Medical University of Vienna 50
Hong Kong Eye Hospital 51
Clinical Trial Overview of Hong Kong Eye Hospital 51
Federal University of Sao Paulo 52
Clinical Trial Overview of Federal University of Sao Paulo 52
University of Sao Paulo 53
Clinical Trial Overview of University of Sao Paulo 53
Five Key Clinical Profiles 54
Appendix 154
Abbreviations 154
Definitions 154
Research Methodology 155
Secondary Research 155
About GlobalData 155
Contact Us 155
Disclaimer 156
Source 156



List of Tables

Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Zone, 2013* 7
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 8
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 9
Diabetic Macular Edema Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2013* 10
Diabetic Macular Edema Therapeutics Clinical Trials, Europe, Top Five Countries, 2013* 11
Diabetic Macular Edema Therapeutics Clinical Trials, North America, Top Countries, 2013* 12
Diabetic Macular Edema Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2013* 13
Diabetic Macular Edema Therapeutics Clinical Trials, Central and South America, Top Countries, 2013* 14
Diabetic Macular Edema Therapeutics Clinical Trials, BRIC Countries, 2013* 15
Diabetic Macular Edema Therapeutics Clinical Trials, G7 Countries, 2013* 16
Diabetic Macular Edema Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 17
Diabetic Macular Edema Therapeutics Clinical Trials, E7 Countries, 2013* 18
Diabetic Macular Edema Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013* 19
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Phase, 2013* 20
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Phase 2013* 21
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 22
Diabetic Macular Edema Therapeutics Market, Global, Suspended Clinical Trials, 2013* 23
Diabetic Macular Edema Therapeutics Market, Global, Withdrawn Clinical Trials, 2013* 24
Diabetic Macular Edema Therapeutics Market, Global, Terminated Clinical Trials, 2013* 25
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 27
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 29
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013* 31
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2013* 33
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2013* 35
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2013* 37
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Regeneron Pharmaceuticals, Inc., 2013* 38
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2013* 39
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2013* 40
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Alimera Sciences, Inc., 2013* 41
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Santen Pharmaceutical Co., Ltd., 2013* 42
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Bausch & Lomb Incorporated, 2013* 43
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Diabetic Retinopathy Clinical Research Network, 2013* 44
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by National Eye Institute, 2013* 45
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Johns Hopkins University, 2013* 46
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Shahid Beheshti University of Medical Sciences, 2013* 47
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Sydney, 2013* 48
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Moorfields Eye Hospital NHS Foundation Trust, 2013* 49
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2013* 50
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Hong Kong Eye Hospital, 2013* 51
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Federal University of Sao Paulo, 2013* 52
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Sao Paulo, 2013* 53



List of Figures

Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Zone (%), 2013* 7
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 8
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 9
Diabetic Macular Edema Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2013* 10
Diabetic Macular Edema Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2013* 11
Diabetic Macular Edema Therapeutics Clinical Trials, North America, Top Countries (%), 2013* 12
Diabetic Macular Edema Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2013* 13
Diabetic Macular Edema Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2013* 14
Diabetic Macular Edema Therapeutics Clinical Trials, BRIC Countries (%), 2013* 15
Diabetic Macular Edema Therapeutics Clinical Trials, G7 Countries (%), 2013* 16
Diabetic Macular Edema Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 17
Diabetic Macular Edema Therapeutics Clinical Trials, E7 Countries (%), 2013* 18
Diabetic Macular Edema Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013* 19
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Phase (%), 2013* 20
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2013* 21
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 22
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 27
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 28
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013* 30
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2013* 32
GlobalData Methodology 155


Read the full report:
Diabetic Macular Edema Global Clinical Trials Review, H2, 2013
http://www.reportbuyer.com/pharma_healthcare/treatments/diabetic_macular...

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
My team embarked on building a data lake for our sales and marketing data to better understand customer journeys. This required building a hybrid data pipeline to connect our cloud CRM with the new Hadoop Data Lake. One challenge is that IT was not in a position to provide support until we proved value and marketing did not have the experience, so we embarked on the journey ourselves within the product marketing team for our line of business within Progress. In his session at @BigDataExpo, Sum...
Niagara Networks exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
Virtualization over the past years has become a key strategy for IT to acquire multi-tenancy, increase utilization, develop elasticity and improve security. And virtual machines (VMs) are quickly becoming a main vehicle for developing and deploying applications. The introduction of containers seems to be bringing another and perhaps overlapped solution for achieving the same above-mentioned benefits. Are a container and a virtual machine fundamentally the same or different? And how? Is one techn...
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
Information technology (IT) advances are transforming the way we innovate in business, thereby disrupting the old guard and their predictable status-quo. It’s creating global market turbulence. Industries are converging, and new opportunities and threats are emerging, like never before. So, how are savvy chief information officers (CIOs) leading this transition? Back in 2015, the IBM Institute for Business Value conducted a market study that included the findings from over 1,800 CIO interviews ...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, will discuss the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information,
Interoute has announced the integration of its Global Cloud Infrastructure platform with Rancher Labs’ container management platform, Rancher. This approach enables enterprises to accelerate their digital transformation and infrastructure investments. Matthew Finnie, Interoute CTO commented “Enterprises developing and building apps in the cloud and those on a path to Digital Transformation need Digital ICT Infrastructure that allows them to build, test and deploy faster than ever before. The int...
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, discussed how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a practic...
In his General Session at 17th Cloud Expo, Bruce Swann, Senior Product Marketing Manager for Adobe Campaign, explored the key ingredients of cross-channel marketing in a digital world. Learn how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects).
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.